MAY 14, 2020 4:40 PM CEST

Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers

  • Marianne Grantham

    Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital


Comprehensive genomic profiling of myeloid and, increasingly more, lymphoid malignancies is becoming an essential part of clinical diagnostics to improve diagnosis, assist therapeutic decisions, and provide better information about prognosis. Introduction of next-generation sequencing (NGS) into the for the profiling can be a solution for future. However it can bring challenges as well as benefits. Our institutions’ journey to introduce NGS into an integrated laboratory is discussed. The practical issues around panel content and data quality are also summarized.


Learning Objectives:

1. Understand the benefits of next-generation sequencing in the profiling  of haematological malignancies 

2. Develop an awareness of the practicalities of introducing new technologies to a medical laboratory

You May Also Like
Loading Comments...
  • See More